SVRA Share Price Performance
US$3.37
-0.40 (-10.61%)
Price US$3.37
Share PriceUS$3.37
Savara Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 6 Fair Values set on narratives written by author
SVRA Community Narratives
There are no narratives available yet.
Savara Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.52
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 24.6%
Savara Inc. Competitors
Snowflake Analysis
About SVRA
- Founded
- 2007
- Employees
- 59
- CEO
- WebsiteView website
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania.
Market Insight
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
U.S. Market Performance
- 7 Days: 0.3%
- 3 Months: 8.5%
- 1 Year: 17.3%
- Year to Date: 15.0%
In the last week, the market has been flat. Meanwhile, the market is actually up 17% over the past year. Earnings are forecast to grow by 15% annually. Market details ›